چاپ صفحه |  صفحه نخست سامانه |  چکیده مقاله |  نویسندگان |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده ثبت کننده مقاله | میترا نیافر |
| مرحله جاری مقاله | تایید نهایی |
| دانشکده/مرکز مربوطه | مرکز تحقیقات غدد درون ریز |
| کد مقاله | 58467 |
| عنوان فارسی مقاله | A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries |
| عنوان لاتین مقاله | A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries |
| ناشر | 4 |
| آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ | خیر |
| عنوان نشریه (خارج از لیست فوق) | |
| نوع مقاله | Review Article |
| نحوه ایندکس شدن مقاله | ایندکس شده سطح یک – ISI - Web of Science |
| آدرس لینک مقاله/ همایش در شبکه اینترنت | http://www.ncbi.nlm.nih.gov/pubmed/26660657 |
| Abstract Purpose Glucagon-like peptides receptor agonists are currently approved as anti-obesity agents, yet the experience with their use in polycystic ovarian syndromes (PCOS)-related obesity and insulin resistance is still limited. Methods We examined the effects of liraglutide on obesity, insulin resistance, and androgen levels in PCOS through a meta-analysis. Results Seven RCTs where women with PCOS were treated with liraglutide were identified. The variables that were examined before and after a 90-day treatment included waist circumference, body mass index (BMI), fasting insulin concentrations, insulin resistance using homeostatic model (HOMA-IR), serum testosterone, and sex hormonebinding globulin (SHBG). The analysis included 178 women. Only 172 patients had post-treatment measurements. While BMI significantly dropped by -1.65 (0.72–2.58) Kg/m2 after 3 months treatment with liraglutide, waist circumference did not change significantly. Similarly, fasting insulin levels, insulin sensitivity, and SHBG did not change significantly. However, serum testosterone decreased by 0.29 nmol/L in 88 women (P = 0.0003). Conclusion In a limited number of the women with PCOS, BMI and serum testosterone are only variables that significantly decrease after 3 months of treatment with GLP-1 receptor agonists. Larger sample size studies with longer durations of treatment may be required to examine potential benefits of these medications in improving insulin sensitivity. |
| نویسنده | نفر چندم مقاله |
|---|---|
| میترا نیافر | اول |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| art_10.1007_s00404-015-3976-7.pdf | 1395/05/11 | 854822 | دانلود |
